Vitae Pharmaceuticals Proposes Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street dips after strong jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil slides on Friday, heads for weekly gain on US-Iran fight
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Vitae Pharmaceuticals (VTAE) Sees 'Substantial' Costs for Developing VTP-43742, VTP-38543, VTP-36951
March 23, 2016 4:18 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) disclosed he following on Wednesday night:
ITEM 7.01. REGULATION FD DISCLOSURE.
On March 23, 2016, Vitae Pharmaceuticals, Inc. (Vitae) announced that Vitae currently anticipates that the net proceeds from the proposed public offering of its common stock,... More
